根治性前列腺切除术后前列腺床放疗对比前列腺床联合盆腔淋巴结放疗的治疗相关毒性:一项全国性人群研究
基于英国国家前列腺癌审计(NPCA)数据库,纳入2010至2016年根治性前列腺切除术后接受放疗的患者,比较前列腺床联合盆腔淋巴结放疗(PBPLN-RT,593例)与仅前列腺床放疗(PBO-RT,5087例)的≥2级胃肠及泌尿生殖毒性。5年累积发生率胃肠毒性分别为15.9%与18.2%,泌尿生殖毒性分别为20.7%与19.1%;校正后两种毒性均无显著差异(胃肠:校正sHR 0.90,95%CI 0.67-1.19,P=0.45;泌尿生殖:校正sHR 1.19,95%CI 0.99-1.44,P=0.09)。
要点
- 根治性前列腺切除术后放疗,联合盆腔淋巴结照射与仅前列腺床照射的≥2级胃肠及泌尿生殖毒性在5年时无显著差异。
- 5年胃肠毒性累积发生率:仅前列腺床组18.2%,联合盆腔淋巴结组15.9%。
- 5年泌尿生殖毒性累积发生率:仅前列腺床组19.1%,联合盆腔淋巴结组20.7%。
核心结论
- 这项全国性人群研究发现,根治性前列腺切除术后将盆腔淋巴结纳入放疗野与5年≥2级胃肠或泌尿生殖毒性发生率显著增加无关。
研究设计与样本
- 利用国家前列腺癌审计(NPCA)数据库识别2010至2016年间根治性前列腺切除术后接受放疗的前列腺癌患者,随访数据截至2018年12月31日。
- 采用基于操作和诊断编码框架的经验证结局指标捕获≥2级胃肠和泌尿生殖毒性,并以校正竞争风险回归分析估计亚分布风险比(sHR)。
主要发现
- 仅前列腺床放疗组(n=5087)与前列腺床联合盆腔淋巴结放疗组(n=593)的5年胃肠毒性累积发生率分别为18.2%和15.9%。
- 仅前列腺床放疗组与联合盆腔淋巴结放疗组的5年泌尿生殖毒性累积发生率分别为19.1%和20.7%。
- 校正后仅前列腺床放疗与联合盆腔淋巴结放疗之间胃肠毒性无差异证据(校正sHR 0.90,95%CI 0.67-1.19,P=0.45)。
- 校正后仅前列腺床放疗与联合盆腔淋巴结放疗之间泌尿生殖毒性无差异证据(校正sHR 1.19,95%CI 0.99-1.44,P=0.09)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose There is debate about the effectiveness and toxicity of pelvic lymph node (PLN) irradiation in addition to prostate bed radiotherapy when used to treat disease recurrence following radical prostatectomy. We compared toxicity from radiation therapy (RT) to the prostate bed and pelvic lymph nodes (PBPLN-RT) with prostatebed only radiation therapy (PBO-RT) following radical prostatectomy. Methods and Materials Patients with prostate cancer who underwent post-prostatectomy RT between 2010 and 2016 were identified by using the National Prostate Cancer Audit (NPCA) database. Follow-up data was available up to December 31, 2018. Validated outcome measures, based on a framework of procedural and diagnostic codes, were used to capture ≥Grade 2 gastrointestinal (GI) and genitourinary (GU) toxicity. An adjusted competing-risks regression analysis estimated subdistribution hazard ratios (sHR). A sHR > 1 indicated a higher incidence of toxicity with PBPLN-RT than with PBO-RT. Results 5-year cumulative incidences in the PBO-RT (n = 5,087) and PBPLNRT (n = 593) groups was 18.2% and 15.9% for GI toxicity, respectively. For GU toxicity it was 19.1% and 20.7%, respectively. There was no evidence of difference in GI or GU toxicity after adjustment between PBO-RT and PBPLN-RT (GI: adjusted sHR, 0.90, 95% CI, 0.67-1.19; P = 0.45); (GU: adjusted sHR, 1.19, 95% CI, 0.99-1.44; P = 0.09). Conclusions This national population-based study found that including PLNs in the radiation field following radical prostatectomy is not associated with a significant increase in rates of ≥Grade 2 GI or GU toxicity at 5 years.
引用
- Sujenthiran A, Parry MG, Dodkins J, et al. Treatment-related toxicity using prostate bed versus prostate bed and pelvic lymph node radiation therapy following radical prostatectomy: A national population-based study. Clin Transl Radiat Oncol. 2023. PMID: 37152844. doi:10.1016/j.ctro.2023.100622
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。